Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy

 
• By Neena Brizmohun
T-cells attacking cancer_1200x675
Bluebird and Celgene's CAR-T therapy makes it on two key regulatory schemes

More from Review Pathways

More from Pathways & Standards